Date of publication: June 25, 2021

Decision of the Secretary of Health: Approved

Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report is produced to present all currently available evidence considered in the assessment of Pfizer-BioNTech COVID-19 Vaccine. This assessment follows the HTAC evaluation framework to assess COVID-19 vaccines which consists of the following criteria: (1) responsiveness to magnitude and severity; (2) clinical efficacy and safety; (3) affordability and viability; (4) household financial impact; (5) social impact; and (6) responsiveness to equity.

Evidence summary: Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) for the prevention of COVID-19

HTAC Updated Recommendation Preview: